ArticleOncology and therapy2026
Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice.
Article in Oncology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with muscle-invasive bladder cancer (MIBC) undergoing radical cystectomy (RC) and pelvic lymph node dissection (PLND) often receive perioperative systemic therapy. However, treatment patterns are evolving with the advent of adjuvant immunotherapy. We examined recent trends in perioperative treatment management in a contemporary cohort of US patients with MIBC undergoing RC in the immunotherapy era.
methodsWe conducted this retrospective, real-world study utilizing N-Power Medicine's Bladder Analytical Dataset to describe demographics, clinical characteristics, and treatment patterns among patients with MIBC who underwent RC between 2021 and 2023. Treatment patterns were further stratified by pathologic high risk of recurrence following RC (ypT2-T4a or ypN+; pT3-4a or pN+).
resultsA total of 138 patients with MIBC who underwent RC were included. The majority were male (82%) and White (83%). Overall, 49% (67/138) of patients received RC without neoadjuvant or adjuvant treatment. Approximately 46% (64/138) received neoadjuvant treatment, mainly gemcitabine and cisplatin. Only 14% (20/138) of all patients received any adjuvant treatment, including 10% (14/138) who received adjuvant nivolumab. Less than 10% of patients (9.4%, 13/138) received both neoadjuvant and adjuvant treatments. Among patients with known pathological staging post-RC (n = 125), approximately half had high risk of disease recurrence (50.4%, 63/125). Among high-risk patients, 22% (14/63) received adjuvant treatment, with 19% (12/63) specifically receiving nivolumab.
conclusionIn this contemporary cohort of patients with MIBC undergoing RC, nearly half received neoadjuvant treatment whereas the use of adjuvant treatment was limited. Since Food and Drug Administration (FDA) approval, adjuvant nivolumab use was approximately 10% in the overall cohort of patients with MIBC treated with RC, and less than 20% among those with a high risk of disease recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.